These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34991106)

  • 21. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
    Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
    Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
    Li Q; Lv M; Jiang H; Wang Y; Yu S; Li W; Yu Y; Liu T
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):287-295. PubMed ID: 31667572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients.
    AbdulHameed Saeed V; Mohammed NAK
    Arch Razi Inst; 2023 Jun; 78(3):981-988. PubMed ID: 38028843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
    Cho JH; Lim JY; Cho JY
    World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of biosimilar trastuzumab MYL-1401O in HER2-positive breast cancer.
    Eser K; Sezer E; Erçolak V; İnal A
    Am J Manag Care; 2023 Feb; 29(2):e36-e42. PubMed ID: 36811986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer.
    Li N; Qiu M; Zhang Y; Yang M; Lu L; Li W; Ma Y; Hou X; Sun G; Cai M; Wang J; Lu J; Zhong D; Huo Z; Zhang J; Yin X; Deng J; Liu Z; Pan H; Chen Y; Yang F; Yu H; Li J; Wang Q; Zhu J; Li J
    Med; 2024 Oct; 5(10):1255-1265.e2. PubMed ID: 38986608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial.
    Zhang QY; Cai RG; Song GH; Li CJ; Zhang BH; Kang XY; Li HP; Xu BH;
    ESMO Open; 2024 Sep; 9(9):103682. PubMed ID: 39241496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.
    Yi JH; Kang JH; Hwang IG; Ahn HK; Baek HJ; Lee SI; Lim DH; Won YW; Ji JH; Kim HS; Rha SY; Oh SY; Lee KE; Lim T; Maeng CH; Kim MJ; Kim ST; Lee J; Park JO; Park YS; Lim HY; Kang WK; Park SH
    Cancer Res Treat; 2016 Apr; 48(2):553-60. PubMed ID: 26323641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
    Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer.
    Bae SJ; Kim JH; Ahn SG; Jeung HC; Sohn J; Kim GM; Kim MH; Kim SI; Park S; Park HS; Kim JY; Jeong J
    Front Oncol; 2021; 11():689587. PubMed ID: 34150658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.
    Wakatsuki T; Yamamoto N; Sano T; Chin K; Kawachi H; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Matsushima T; Suenaga M; Shinozaki E; Hiki N; Ishikawa Y; Yamaguchi K
    J Gastroenterol; 2018 Nov; 53(11):1186-1195. PubMed ID: 29633013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.
    Jeon C; Kang SH; Kim SB; Paik NS; Lee I; Kim SK; Kim EY; Son GS; Yoo YB; Lee KH; Shin J; Ju S; Jang H; Park MH
    Oncology; 2024; 102(6):465-475. PubMed ID: 37899039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis.
    Ilhan-Mutlu A; Taghizadeh H; Beer A; Dolak W; Ba-Ssalamah A; Schoppmann SF; Hejna M; Birner P; Preusser M
    Cancer Biol Ther; 2018 Mar; 19(3):169-174. PubMed ID: 29252101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.
    Kolberg HC; Colleoni M; Demetriou GS; Santi P; Tesch H; Fujiwara Y; Tomasevic Z; Hanes V
    Drug Saf; 2020 Mar; 43(3):233-242. PubMed ID: 31927716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment.
    Xu C; Liu Y; Jiang D; Ge X; Huang J; Su J; Zhang X; Lu S; Ji Y; Hou J; Liu T; Hou Y
    Aging (Albany NY); 2019 Nov; 11(22):10052-10060. PubMed ID: 31739285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of action of the trastuzumab biosimilar CT-P6.
    Jeong SA; Choi JM; Park JM; Lee JY; Lee SJ; Lee SY; Lee SY; Park YA; Jeong HJ; Song YC; Kim SH; Chang SJ
    Expert Opin Biol Ther; 2019 Oct; 19(10):1085-1095. PubMed ID: 30541352
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
    Yagi S; Wakatsuki T; Yamamoto N; Chin K; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Shinozaki E; Suenaga M; Fujisaki J; Ishikawa Y; Yamaguchi K; Namikawa K; Horiuchi Y
    Gastric Cancer; 2019 May; 22(3):518-525. PubMed ID: 30328533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
    Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
    Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.